Search results
FDA grants orphan drug status to tafenoquine for babesiosis By Investing.com
Investing.com· 6 days agoThe U.S. Food and Drug Administration (FDA) has awarded orphan drug designation to 60 Degrees...
US Drug Negotiations Plan Shifts Focus for Rare Disease Programs
Bloomberg Law· 13 hours agoThe rare disease community is pushing for changes in the Inflation Reduction Act’s drug price-setting scheme as it leads more drugmakers and investors to reconsider development of drugs to treat ...
Race Oncology awarded Orphan Drug designation extension for RC220 for acute myeloid leukemia; shares...
Proactive Investors· 7 days agoRace Oncology Ltd (ASX:RAC, OTC:RAONF) has welcomed the extension of the company’s proprietary...
Stocks In Play: Cardiol Therapeutics Inc. By Baystreet.ca
Investing.com· 12 hours agoStocks In Play: Cardiol Therapeutics Inc.
Citi maintains Buy rating on Cabaletta Bio post-EULAR data By Investing.com
Investing.com· 12 hours agoOn Monday, Citi reaffirmed its positive stance on Cabaletta Bio Inc . The endorsement follows the...
Elion secures $81m to advance antifungal therapy
Pharmaceutical Technology via Yahoo Finance· 4 hours agoElion’s antifungal therapy SF001 targets aspergillosis, which can be caused by Aspergillus fumigatus, a pathogen of critical priority as per the WHO.
Exploring Undervalued Small Caps With Insider Buying In Hong Kong June 2024
Simply Wall St. via Yahoo Finance· 14 hours agoAs of June 2024, the Hong Kong market reflects a cautious sentiment, mirroring broader global...
OS Therapies Inc. Prices IPO at $4.00 Per Share (OSTX)
ETF DAILY NEWS· 2 days agoOS Therapies Inc. (OSTX) plans to raise $8 million in an initial public offering on Thursday, June 20th, IPO Scoop reports. The company will be issuing 2,000,000 shares at a price of $4.00 per ...
Exploring Three Swedish Exchange Growth Companies With High Insider Ownership
Simply Wall St. via Yahoo Finance· 6 days agoAs global markets navigate through mixed economic signals, Sweden's market remains a focal point for...
Mitsubishi Tanabe Pharma America Celebrates Second Anniversary of RADICAVA ORS® (edaravone) Launch...
WWTI Watertown· 9 hours ago"Helping people who are living with serious and debilitating diseases is our greatest motivator, and we are honored that for two years, RADICAVA ORS has provided people with ALS an oral treatment ...
